According to filings with the U.S. Securities and Exchange Commission, Oric Pharmaceuticals is raising up to $125,000,000.00 in new funding. Sources indicate that as part of senior management President and Chief Executive Officer, Jacob Chacko played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Oric Pharmaceuticals
Our Story ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients lives by Overcoming Resistance In Cancer. ORICs clinical stage product candidates include (1) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, being developed for multiple myeloma, (2) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, and (3) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer. Beyond these three product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California.

To learn more about Oric Pharmaceuticals, visit http://oricpharma.com/

Contact:
Jacob Chacko, President and Chief Executive Officer
650-388-5600
https://www.linkedin.com/in/jacob-chacko-m-d-73b8802/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.